Please check your internet connection and try again.
## Ticagrelor
### Overview
Ticagrelor is an orally administered, direct-acting, reversible P2Y12 receptor antagonist.
### Primary Indications
* Inhibition of platelet aggregation in patients with a history of myocardial infarction (MI) or with acute coronary syndrome (ACS).
### Adult Dosing
* **ACS:** A 180 mg loading dose, followed by 90 mg twice daily for at least 12 months.
* **History of MI:** 60 mg twice daily.
* **Note:** Duration of therapy may vary based on individual patient factors and local protocols.
### Pediatric Dosing
* Information regarding the safety and efficacy of ticagrelor in pediatric patients is not established.
### Dose Adjustments
* No dose adjustment is necessary for patients with mild to moderate hepatic impairment. Safety and efficacy in severe hepatic impairment have not been studied.
* No dose adjustment is necessary for patients with mild to moderate renal impairment. Safety and efficacy in severe renal impairment or end-stage renal disease have not been studied.
### Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any of its excipients.
### Adverse Effects
* **Common:** Dyspnea, bruising, bleeding (including life-threatening and fatal bleeding).
* **Serious:** Severe bleeding, ventricular pauses (particularly with concomitant CYP3A4 inhibitors or in patients with predisposing factors).
### Key Drug Interactions
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir, clarithromycin):** Increased ticagrelor exposure and risk of bleeding. Coadministration with strong CYP3A4 inhibitors is generally not recommended.
* **CYP3A4 Inducers (e.g., rifampin, phenytoin, carbamazepine):** Decreased ticagrelor exposure.
* **Aspirin:** Concomitant use with aspirin increases bleeding risk. Ticagrelor should be used with aspirin for ACS.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding.
### Monitoring
* Monitor for signs and symptoms of bleeding.
* Regularly assess renal and hepatic function, especially in patients with pre-existing impairment.
### Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel.
* Dyspnea is a common side effect and may require discontinuation if severe or persistent.
* Discontinuation of ticagrelor increases the risk of thrombotic events. Avoid premature discontinuation.
* Consider the potential for bradyarrhythmias, especially in patients with risk factors.
***
*This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information for ticagrelor.*
